David Young

TL;DR: Indacaterol and tiotropium provided clinically relevant improvements in lung function with comparable safety profiles and the present data offer evidence consistent with current guidelines.

TL;DR: It is demonstrated that patients with moderate COPD and no exacerbations in the previous year can be switched from SFC to indacaterol 150 μg with no efficacy loss.

TL;DR: Once daily indacaterol 300 μg produced effective sustained 24-h bronchodilation from the first dose, an efficacy profile superior to placebo and twice daily salmeterol, and is likely to be a useful treatment option for patients with moderate-to-severe COPD.

TL;DR: Breathlessness may be an important marker of overall disease severity, indicating the presence of cardiac co-morbidities in the GOLD categories.

TL;DR: Indacaterol was developed using a combination of informed drug design and molecular chemistry to generate a β2-adrenergic agonist with a fast onset and long duration of action, enabling once-daily dosing with an acceptable safety profile.